Aim: to evaluate the efficacy and duration of the therapeutic effect of dequalinium chloride (in comparison with clindamycin) in treatment of vaginal dysbiosis. Materials and methods. A total of 73 fertile-aged women (18-35 years old) with abnormal vaginal microbiota were examined. The patients were randomized into two groups: Group 1 (main) included 37 women receiving dequalinium chloride; Group 2 (control) included 36 women under clindamycin therapy. The efficacy was assessed by analyzing patients’ complaints, by gynecological examinations, pH values of the vaginal fluid, the Amsel criteria, the microscopy results and the polymerase chain reaction (PCR). Results. Before the treatment, the Amsel criteria were positive in 36 patients (97.29%) in the main group and in 31 patients (93.93%) in the control group; all patients showed an increase in the pH values of the vaginal fluid by more than 4.5 units. The state of vaginal microbiocenosis as evaluated with RT-PCR diagnostics (Femoflor 16 analysis) identified a variety of gram-positive and gram-negative bacteria with a marked decrease in the number of Lactobacilli. During the treatment period, there were no complaints of adverse events; pH values were normal in all patients; the Femoflor 16 analysis showed a significant decrease in the amounts of pathogenic microorganisms. As assessed in 1 month after the treatment, the therapeutic effect persisted. Conclusion. The dequalinium chloride has antibacterial effect on bacterial vaginosis. The results of the study showed that dequalinium chloride had the efficacy comparable with that of clindamycin.
In obstetric practice, the search for reserves to increase the effectiveness of prevention of gestational complications associated with infectious and inflammatory diseases of the urinaiy system is relevant. The purpose of this study was to assess the results of using the Canephron® N herbal medicine in pregnant women with chronic pyelonephritis. The study included 100 women, randomly divided into four groups, three of which were carried out for prophylactic use of the drug Canephron®N, and were not prescribed phytoprophylaxis in the fourth. It has been established that monotherapy with Canephron®N reduces the risk of exacerbations of chronic pyelonephritis, improves the functional state of the urinary tract, reduces the incidence of bacteriuria. Optimal results are achieved with the use of prophylactic courses of Canephron®N at the gestational period of 10-12, 22-24, and 34-36 weeks.
Проблема патологии шейки матки и, в частности, ее воспалительные изменения остаются актуальными в на-стоящее время, поскольку отмечается рост числа хрониче-ских цервицитов, а также имеет место опасность развития злокачественных процессов с неблагоприятным исходом.Этиологические факторы воспалительных процессов в экзо-и эндоцервиксе могут быть представлены как не-специфическими факультативно-анаэробными грампо-ложительными микроорганизмами (Staphylococcus spp., Streptococcus spp., M. hominis, U. urealiticum и др.), так и Цель исследования -оценка эффективности локальной цитокинотерапии при лечении женщин раннего репродуктив-ного возраста с цервицитами. Материал и методы. Представлены результаты исследования эффективности локальной цитокинотерапии при лечении цервицитов у 70 нерожавших женщин репродуктивного возраста 19-25 лет с клиниче-скими и лабораторными признаками цервицита. В 1-ю группу вошли 32 женщины, получавшие базовую противовоспа-лительную терапию, во 2-ю -38 женщин, получавших кроме базовой терапии отечественный иммунотропный препарат суперлимф. Использованы клинические, лабораторные, кольпоскопические методы обследования. Результаты. Отмечено достоверное улучшение оцениваемых клинических параметров в обеих группах. Выявлена более высокая эффективность терапии во 2-й группе. В 1-й группе через 3 мес имел место рецидив симптомов у 31,3±8,2% женщин, во 2-й -у 5,3±3,6% (р 1-2 <0,01). Заключение. Иммунотропный препарат Суперлимф способствует устранению патологических нарушений локальных иммунорегуляторных механизмов, позволяет избежать рецидивирования воспалительного процесса, снизить риск реализации дисплазии эпителия на фоне хронического цервицита.Авторы информируют об отсутствии конфликта интересов. Objective -to evaluate the efficiency of local cytokine therapy in early reproductive-aged women with cervititis. Material and methods. The results of investigating the efficiency of local cytokine therapy for cervititis were analyzed in 70 nulliparae of reproductive age 19-25 years with clinical and laboratory signs of this condition. Group 1 included 32 women who received basic anti-inflammatory therapy; Group 2 consisted of 38 women who took the Russian immunotropic drug Superlimf in addition to the basic therapy. Clinical, laboratory, and colposcopic examinations were used. Results. A significant improvement in the rated clinical parameters was noted in both groups. The therapy in Group 2 was found to be more highly effective. Following 3 months, there was a relapse in 31.3±8.2% of the women in Group 1 and 5.3±3.6% in Group 2 (р 1-2 <0.01). Conclusion. The immunotropic drug Superlimf contributes to the elimination of impaired local immunoregulatory mechanisms and allows avoidance of recurrent inflammation and a reduction of the risk of epithelial dysplasia in the presence of chronic cervititis. Ключевые слова: патология шейки матки, цервицит, локальная цитокинотерапия, суперлимф. Optimization of local cytokine therapy for cervititis at an early reproductive ageThe authors declare no conflicts of interest.
Фетоплацентарная недостаточность является важной проблемой акушерства, и приводит к формированию син-дрома задержки роста плода. Стандартной схемы лечения существовать не может вследствие индивидуального соче-тания этиологических факторов и патогенетических механизмов развития данного осложнения. Проведено ретроспек-тивное и проспективное обследование 80 беременных женщин на сроках гестации от 28 до 36 недель. При анализе результатов инструментальных методов исследования после фармакологической коррекции выявлено равноценное улучшение показателей гемодинамики как в маточных сосудах, так и в артерии пуповины плода, что обусловлено действием препарата «Флебодиа 600» ® , тогда как «Пентоксифиллин» ® оказывает частичное положительное действие на маточный и плацентарный кровоток.Ключевые слова: фетоплацентарная недостаточность, синдром задержки роста плода, флебодиа 600, пентокси-филлин, ангиопротектор. COMPARATIVE ANALYSIS OF PHARMACOLOGICAL EFFICACY OF ANGIOPROTECTIVE AGENTS IN THE TREATMENT OF FETAL GROWTH RETARDATION SYNDROME Klycheva O.I., Khuraseva A.B. Department of Obstetrics and Gynecology of Kursk State Medical University, KurskFetoplacental insufficiency is an important problem of obstetrics, and this pathological condition leads to the development of fetal growth retardation syndrome. Standard treatment regimens cannot be available due to a combination of individual etiological factors and pathogenetic mechanisms of developing this complication. The retrospective and prospective survey of 80 pregnant women in terms of gestation from 28 to 36 weeks was performed. When analyzing the results of instrumental research methods after pharmacological correction, an equivalent improvement in hemodynamic parameters was revealed in both the uterine vessels and in the artery of the umbilical cord, which is due to the action of the preparation «Flebodia 600» ® , whereas «Pentoxifylline» ® has a partial positive effect on uterine and placental blood flow.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.